Among the previously-identified biomarkers for anti-PD1 therapeutic response, PD-L1 immunohistochemistry (IHC) was first approved by the United States Food and Drug Administration (FDA) as a companion test in NSCLC 3. Here, CD274 is linked to non-small cell lung carcinoma.